Alexander Viktorin1,2,3, Rudolf Uher4, Alexander Kolevzon1,2, Abraham Reichenberg1,2, Stephen Z Levine5, Sven Sandin1,2,3. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York. 2. The Seaver Autism Center for Research and Treatment, Mount Sinai, New York, New York. 3. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 4. Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada. 5. Department of Community Mental Health, University of Haifa, Haifa, Israel.
Abstract
Importance: Maternal antidepressant medication use during pregnancy has previously been associated with adverse outcomes in offspring, but to our knowledge, the association with intellectual disability (ID) has not been investigated. Objectives: To examine the association of maternal antidepressant medication use during pregnancy with ID in offspring and investigate the importance of parental mental illness for such an association. Design, Setting, and Participants: A population-based cohort study of 179 007 children born from January 1, 2006, through December 31, 2007, with complete parental information from national registers who were followed up from birth throughout 2014. Main Outcomes and Measures: We estimated relative risks (RRs) and 95% CIs of ID in children exposed during pregnancy to any antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all other non-SSRI antidepressants, or other nonantidepressant psychotropic medications. Analyses were adjusted for potential confounders. In addition to full population analyses, we used a subsample to compare mothers who used antidepressants during pregnancy with mothers who had at least one diagnosis of depression or anxiety before childbirth but did not use antidepressants during pregnancy. Results: Of the 179 007 children included in the study (mean [SD] age at end of follow-up, 7.9 [0.6] years; 92 133 [51.5%] male and 86 874 [48.5%] female), ID was diagnosed in 37 children (0.9%) exposed to antidepressants and in 819 children (0.5%) unexposed to antidepressants. With adjustment for potential confounders, the RR of ID after antidepressant exposure was estimated at 1.33 (95% CI, 0.90-1.98) in the full population sample and 1.64 (95% CI, 0.95-2.83) in the subsample of women with depression. Results from analyses of SSRI antidepressants, non-SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically relevant subsample did not deviate from the full-sample results. Conclusions and Relevance: The unadjusted RR of ID was increased in offspring born to mothers treated with antidepressants during pregnancy. After adjustment for confounding factors, however, the current study did not find evidence of an association between ID and maternal antidepressant medication use during pregnancy. Instead, the association may be attributable to a mechanism integral to other factors, such as parental age and mother's psychiatric disorder.
Importance: Maternal antidepressant medication use during pregnancy has previously been associated with adverse outcomes in offspring, but to our knowledge, the association with intellectual disability (ID) has not been investigated. Objectives: To examine the association of maternal antidepressant medication use during pregnancy with ID in offspring and investigate the importance of parental mental illness for such an association. Design, Setting, and Participants: A population-based cohort study of 179 007 children born from January 1, 2006, through December 31, 2007, with complete parental information from national registers who were followed up from birth throughout 2014. Main Outcomes and Measures: We estimated relative risks (RRs) and 95% CIs of ID in children exposed during pregnancy to any antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all other non-SSRI antidepressants, or other nonantidepressant psychotropic medications. Analyses were adjusted for potential confounders. In addition to full population analyses, we used a subsample to compare mothers who used antidepressants during pregnancy with mothers who had at least one diagnosis of depression or anxiety before childbirth but did not use antidepressants during pregnancy. Results: Of the 179 007 children included in the study (mean [SD] age at end of follow-up, 7.9 [0.6] years; 92 133 [51.5%] male and 86 874 [48.5%] female), ID was diagnosed in 37 children (0.9%) exposed to antidepressants and in 819 children (0.5%) unexposed to antidepressants. With adjustment for potential confounders, the RR of ID after antidepressant exposure was estimated at 1.33 (95% CI, 0.90-1.98) in the full population sample and 1.64 (95% CI, 0.95-2.83) in the subsample of women with depression. Results from analyses of SSRI antidepressants, non-SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically relevant subsample did not deviate from the full-sample results. Conclusions and Relevance: The unadjusted RR of ID was increased in offspring born to mothers treated with antidepressants during pregnancy. After adjustment for confounding factors, however, the current study did not find evidence of an association between ID and maternal antidepressant medication use during pregnancy. Instead, the association may be attributable to a mechanism integral to other factors, such as parental age and mother's psychiatric disorder.
Authors: Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg Journal: Br J Clin Pharmacol Date: 2007-10-22 Impact factor: 4.335
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Bruce P Lanphear; Richard Hornung; Jane Khoury; Kimberly Yolton; Peter Baghurst; David C Bellinger; Richard L Canfield; Kim N Dietrich; Robert Bornschein; Tom Greene; Stephen J Rothenberg; Herbert L Needleman; Lourdes Schnaas; Gail Wasserman; Joseph Graziano; Russell Roberts Journal: Environ Health Perspect Date: 2005-07 Impact factor: 9.031
Authors: Magdalena Janecka; Arad Kodesh; Stephen Z Levine; Shari I Lusskin; Alexander Viktorin; Rayees Rahman; Joseph D Buxbaum; Avner Schlessinger; Sven Sandin; Abraham Reichenberg Journal: JAMA Psychiatry Date: 2018-12-01 Impact factor: 21.596
Authors: Jennifer L Ames; Christine Ladd-Acosta; M Daniele Fallin; Yinge Qian; Laura A Schieve; Carolyn DiGuiseppi; Li-Ching Lee; Eric P Kasten; Guoli Zhou; Jennifer Pinto-Martin; Ellen M Howerton; Christopher L Eaton; Lisa A Croen Journal: Biol Psychiatry Date: 2021-04-14 Impact factor: 12.810